These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 35774131)

  • 1. Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability.
    Yu G; Wang W; He X; Xu J; Xu R; Wan T; Wu Y
    Front Oncol; 2022; 12():895103. PubMed ID: 35774131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype.
    Kang S; Wang L; Xu L; Wang R; Kang Q; Gao X; Yu L
    Oncogene; 2022 Oct; 41(42):4696-4708. PubMed ID: 36097193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
    Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A rare population of tumor antigen-specific CD4
    Matsuzaki J; Tsuji T; Chodon T; Ryan C; Koya RC; Odunsi K
    J Immunother Cancer; 2019 Jan; 7(1):7. PubMed ID: 30626427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
    Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.
    Chou J; Voong LN; Mortales CL; Towlerton AM; Pollack SM; Chen X; Yee C; Robbins PF; Warren EH
    J Immunother; 2012; 35(2):131-41. PubMed ID: 22306901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma.
    Everson RG; Antonios JP; Lisiero DN; Soto H; Scharnweber R; Garrett MC; Yong WH; Li N; Li G; Kruse CA; Liau LM; Prins RM
    Neuro Oncol; 2016 Mar; 18(3):368-78. PubMed ID: 26330563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of NY-ESO-1
    Zhang H; Sun M; Wang J; Zeng B; Cao X; Han Y; Tan S; Gao GF
    Front Immunol; 2021; 12():644520. PubMed ID: 33833762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A potential role for immunotherapy in thyroid cancer by enhancing NY-ESO-1 cancer antigen expression.
    Gunda V; Frederick DT; Bernasconi MJ; Wargo JA; Parangi S
    Thyroid; 2014 Aug; 24(8):1241-50. PubMed ID: 24811699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma.
    Ishihara M; Nishida Y; Kitano S; Kawai A; Muraoka D; Momose F; Harada N; Miyahara Y; Seo N; Hattori H; Takada K; Emori M; Kakunaga S; Endo M; Matsumoto Y; Sasada T; Sato E; Yamada T; Matsumine A; Nagata Y; Watanabe T; Kageyama S; Shiku H
    Int J Cancer; 2023 Jun; 152(12):2554-2566. PubMed ID: 36727538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report.
    Xia Y; Tian X; Wang J; Qiao D; Liu X; Xiao L; Liang W; Ban D; Chu J; Yu J; Wang R; Tian G; Wang M
    Oncol Lett; 2018 Dec; 16(6):6998-7007. PubMed ID: 30546433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific Inhibition of Tumor Growth by T Cell Receptor-Drug Conjugates Targeting Intracellular Cancer-Testis Antigen NY-ESO-1/LAGE-1.
    Qiu CX; Bai XF; Shen Y; Zhou Z; Pan LQ; Xu YC; Zhao WB; Chen SQ
    Bioconjug Chem; 2020 Dec; 31(12):2767-2778. PubMed ID: 33237767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decitabine immunosensitizes human gliomas to NY-ESO-1 specific T lymphocyte targeting through the Fas/Fas ligand pathway.
    Konkankit VV; Kim W; Koya RC; Eskin A; Dam MA; Nelson S; Ribas A; Liau LM; Prins RM
    J Transl Med; 2011 Nov; 9():192. PubMed ID: 22060015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with decitabine induces the expression of stemness markers, PD-L1 and NY-ESO-1 in colorectal cancer: potential for combined chemoimmunotherapy.
    Taib N; Merhi M; Inchakalody V; Mestiri S; Hydrose S; Makni-Maalej K; Raza A; Sahir F; Azizi F; Nizamuddin PB; Fernandes Q; Yoosuf ZSKM; Almoghrabi S; Al-Zaidan L; Shablak A; Uddin S; Maccalli C; Al Homsi MU; Dermime S
    J Transl Med; 2023 Mar; 21(1):235. PubMed ID: 37004094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liposome-based in situ antigen-modification strategy for "universal" T-cell-receptor engineered T cell in cancer immunotherapy.
    Wang Q; Peng R; Qi H; Xu R; Liu W; Meng F; Du S; Yu L; Wei J; Liu F; Li R
    MedComm (2020); 2024 Jul; 5(7):e618. PubMed ID: 38974711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
    Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
    J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allorestricted T lymphocytes with a high avidity T-cell receptor towards NY-ESO-1 have potent anti-tumor activity.
    Krönig H; Hofer K; Conrad H; Guilaume P; Müller J; Schiemann M; Lennerz V; Cosma A; Peschel C; Busch DH; Romero P; Bernhard H
    Int J Cancer; 2009 Aug; 125(3):649-55. PubMed ID: 19444908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulatory action of the DNA methyltransferase inhibitor SGI-110 in epithelial ovarian cancer cells and xenografts.
    Srivastava P; Paluch BE; Matsuzaki J; James SR; Collamat-Lai G; Taverna P; Karpf AR; Griffiths EA
    Epigenetics; 2015; 10(3):237-46. PubMed ID: 25793777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.
    Singh N; Kulikovskaya I; Barrett DM; Binder-Scholl G; Jakobsen B; Martinez D; Pawel B; June CH; Kalos MD; Grupp SA
    Oncoimmunology; 2016; 5(1):e1040216. PubMed ID: 26942053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NY-ESO-1 antigen-reactive T cell receptors exhibit diverse therapeutic capability.
    Sommermeyer D; Conrad H; Krönig H; Gelfort H; Bernhard H; Uckert W
    Int J Cancer; 2013 Mar; 132(6):1360-7. PubMed ID: 22907642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.